Xenetic Biosciences Inc. (XBIO)
NASDAQ: XBIO
· Real-Time Price · USD
2.93
0.01 (0.17%)
At close: Aug 15, 2025, 12:18 PM
Xenetic Biosciences Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.08M | -3.67M | -3.96M | -4.08M | -4.7M | -4.47M | -4.13M | -4.45M | -4.19M | -5.82M | -6.55M | -6.91M | -7.46M | -5.89M | -5.65M | -5M | -11.21M | -11.06M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 19.09K | 27.04K | 36.66K | 46.13K | 36.33K | 37.41K | 36.54K | 35.48K | 34.24K | 31.48K | 29.84K |
Stock-Based Compensation | 87.58K | 113.99K | 171.81K | 221.28K | 264.01K | 291.31K | 283.08K | 327.16K | 394.26K | 460.74K | 511.48K | 505.93K | 479.7K | 453.75K | 410.44K | 378.12K | 377.79K | 379.6K |
Other Working Capital | 998.86K | 942.85K | 886.3K | 978.55K | 288.73K | 150.57K | 845.00 | -460.04K | -490.76K | 88.63K | -78.74K | -219.68K | 14.58K | -151.53K | 4.06K | 95.68K | 159.13K | 302.38K |
Other Non-Cash Items | 171.19K | n/a | n/a | n/a | -126.92K | -72.48K | 213.17K | 682.83K | 1.19M | 2.44M | 2.64M | 2.63M | 2.23M | 898.99K | 653.4K | 3.11M | 6.54M | 6.42M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -381.6K | -381.6K | -381.6K | -842.79K | -461.19K | -461.19K | -461.19K | -2.92M | n/a | n/a |
Change in Working Capital | 305.52K | 894.29K | 970.98K | 919.46K | 1.01M | 10.7K | -262.73K | -442.4K | -898.63K | -118.27K | -426.69K | -290.31K | 327.59K | 95.98K | 461.19K | 358.14K | 267.41K | -316.08K |
Operating Cash Flow | -2.52M | -2.66M | -2.82M | -2.94M | -3.43M | -4.17M | -4.11M | -4.07M | -4.2M | -3.66M | -4.65M | -5.35M | -5.31M | -5.31M | -4.74M | -4.23M | -4.21M | -4.79M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | -500K | -500K | -500K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | -500K | -1M | -1M | -500K | -500K | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -500K | -500K | -1M | -1M | -500K | -500K | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.29M | 1.29M | 1.29M | 1.29M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -805K | -805K | -805K | -805K | 3.68K | 11.46M | 11.46M | 11.46M | 11.45M | n/a | n/a |
Financial Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -805K | -805K | -805K | -805K | 11.45M | 22.91M | 22.91M | 22.91M | 16.88M | 5.43M | 5.43M |
Net Cash Flow | -2.52M | -2.66M | -2.82M | -2.94M | -3.43M | -4.17M | -4.11M | -4.07M | -4.2M | -4.16M | -5.15M | -5.85M | 5.65M | 6.15M | 6.72M | 12.65M | 1.22M | 641.16K |
Free Cash Flow | -2.52M | -2.66M | -2.82M | -2.94M | -3.43M | -4.17M | -4.11M | -4.07M | -4.2M | -3.66M | -4.65M | -5.35M | -5.31M | -5.31M | -4.74M | -4.23M | -4.21M | -4.79M |